Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

NCT02876107 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Breast Carcinoma
Breast Lump
Edema
Erythema
Estrogen Receptor Negative
HER2/Neu Negative
Inflammatory Breast Carcinoma
Invasive Breast Carcinoma
Peau d'Orange
Progesterone Receptor Negative
Triple-Negative Breast Carcinoma

Interventions

DRUG: Carboplatin
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel
BIOLOGICAL: Panitumumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]